Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Astellas collaborates with Proteostasis on UPR candidates in possible $1.2bn deal

Executive Summary

Proteostasis Therapeutics Inc. (mostly focused on orphan and neurodegenerative diseases caused by defects in protein folding, trafficking, and clearance) and Astellas Pharma Inc. will research and develop therapeutic candidates that modulate the unfolded protein response (UPR) pathway.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies